ArticleCost effectiveness and resource allocation : C/E2026
Institutional budget impact and financial viability of a trimodal prehabilitation program in oncologic surgery: a five-year analysis in a public hospital.
Article in Cost effectiveness and resource allocation : C/E, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlthough trimodal prehabilitation programs have demonstrated clinical benefits in oncologic surgery, evidence regarding their financial sustainability in public health systems of middle-income countries remains limited.
objectiveTo assess the institutional budget impact and financial viability of implementing a trimodal prehabilitation program for oncologic surgical patients in a public regional hospital.
methodsA five-year Budget Impact Analysis was conducted from the hospital perspective. The model incorporated an initial capital investment of CLP 24,773,549 and an annual operating cost of CLP 92,400,000, with a projected annual enrollment of 380 patients. Cost offsets were primarily driven by expected reductions in postoperative hospital length of stay, while reductions in major postoperative complications were incorporated as complementary clinical-economic indicators. A 10% annual discount rate was applied. Net present value (NPV) and internal rate of return (IRR) were calculated to assess financial performance.
resultsThe estimated cost per treated patient was CLP 243,158, while projected annual cost offsets averaged CLP 287,000 per patient. The program generated an annual net benefit of approximately CLP 16,660,000. Over a five-year horizon, the discounted NPV was CLP 38,382,700, with an IRR of 43%. Sensitivity analyses demonstrated that financial viability was primarily dependent on the magnitude of hospital length-of-stay reduction.
conclusionUnder base-case assumptions, implementation of a trimodal prehabilitation program in a public hospital setting appears financially sustainable, with projected returns exceeding the institutional discount threshold. These findings suggest that perioperative optimization strategies may represent an economically viable investment for resource-constrained health systems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.